Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: Radiobiological and immunologic strategies;Antitumorale wirkung von interferonen und interleukinen in kombination mit strahlentherapie. Teil II: Strahlenbiologische und immunologische strategien

Strahlentherapie und Onkologie

Volumn 180, Issue 6, 2004, Pages 331-339

  Herskind, Carsten ^a,b   Fleckenstein, Katharina ^b   Lohr, Jens ^c   Li, Chuan Yuan ^d   Wenz, Frederik ^b   Lohr, Frank ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Institut fur Klinische Radiologie   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biological response modifiers; Cytokines; Immune response; Interferon; Interleukin; Radiotherapy; Tumor associated antigens (TAA)

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; INTERFERON; INTERLEUKIN 12; ISOTRETINOIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; VASCULOTROPIN;

ANIMAL MODEL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IONIZING RADIATION; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MOUSE; NASOPHARYNX CANCER; NEUTRON RADIATION; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKINS; NEOPLASMS; RADIOTHERAPY;

EID: 2642554030     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-8119-1     Document Type: Review

References (78)

1. Addison CL, Bramson JL, Hitt MM, et al. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 1998;5:1400-9.
2. Agarwala SS. Interferon-alpha and -beta: clinical applications - epithelial cancers. In: Rosenberg SA, ed. Principles and practice of the biological therapy of cancer, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000:275-85.
3. Angioli R, Sevin BU, Perras JP, et al. In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines. Cancer 1993;71:3717-25.
4. Atzpodien J, Neuber K, Kamanabrou D, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002;86:179-84.
5. Blaese MA, Santo-Hoeltje L, Rodemann HP. Sensitivity of human tumor cells to retinoids or combined treatment with retinoids and ionizing radiation is not dependent on RAR-beta 2 induction. Strahlenther Onkol 2003; 179:401-9.
6. Blase M, Zaruba MM, Santo-Hoeltje L, et al. 13-cis retinoic acid in combination with interferon-alpha enhances radiation sensitivity of human squamous cell carcinoma cells of the oral cavity. Strahlenther Onkol 1999; 175:563-8.
7. Bradley JD, Scott CB, Paris KJ, et al. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys 2002;52:1173-9.
8. Brinkmann OA, Bruns F, Prott FJ, et al. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). Anticancer Res 1999;19:1583-7.
9. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
10. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001;92:420-33.
11. Chang AY, Keng PC. Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle. Cancer Res 1987;47:4338-41.
12. Cohen EE, Vokes EE. Searching for a standard. J Clin Oncol 2002;20:359-61.
13. Connors JM, Andiman WA, Howarth CB, et al. Treatment of nasopharyngeal carcinoma with human leukocyte interferon. J Clin Oncol 1985;3:813-7.
14. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441-52.
15. DeLaney TF, Afridi N, Taghian AG, et al. 13-cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res 1996;56:2277-80.
16. Dillman RO, Shea WM, Tai DF, et al. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neurooncology 2001; 3:35-41.
17. Dunst J, Becker A, Lautenschlager C, et al. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 2002;178:436-41.
18. Dunst J, Hansgen G, Krause U, et al. A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers. Strahlenther Onkol 1998; 174:571-4.
19. Dunst J, Hansgen G, Lautenschlager C, et al. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. Int J Radiat Oncol Biol Phys 1999;43:367-73.
20. Dunst J, Stadler P, Becker A, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003;179:521-6.
21. Farkkila M, Jaaskelainen J, Kallio M, et al. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 1994;70:138-41.
22. + T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J Immunol 1999;162:609-17.
23. Gould MN, Kakria RC, Olson S, et al. Radiosensitization of human bronchogenic carcinoma cells by interferon beta. J Interferon Res 1984;4:123-8.
24. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-9.
25. Hazard LJ, Sause WT, Noyes RD. Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys 2002;52:796-800.
26. Hillman GG, Maughan RL, Gdgnon DJ, et al. Neutron or photon irradiation for prostate tumors: enhancement of cytokine therapy in a metastatic tumor model. Clin Cancer Res 2001;7:136-44.
27. Hoffmann W, Blase MA, Santo-Hoeltje L, et al. Radiation sensitivity of human squamous cell carcinoma cells in vitro is modulated by all-trans and 13-cis-retinoic acid in combination with interferon-alpha. Int J Radiat Oncol Biol Phys 1999;45:991-8.
28. Hoffmann W, Schiebe M, Hirnle P, et al. 13-cis retinoic acid and interferon-alpha +/- irradiation in the treatment of squamous-cell carcinomas. Int J Cancer 1997;70:475-7.
29. Hunter N, Nakayama T, Ito H, et al. Combination of interleukin-2 and irradiation in therapy of murine tumors. Clin Exp Metastasis 1992;10:431-6.
30. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14-7.
31. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994;12:2321-6.
32. Johansson S, Landstrom M, Hellstrand K, et al. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br J Cancer 1998;77:1213-9.
33. Jurgenliemk-Schulz IM, Renes IB, Rutgers DH, et al. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Radiat Oncol Investig 1997;5:54-61.
34. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-9.
35. Kimura M, Yoshida Y, Narita M, et al. Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus. Int J Cancer 1999;82:549-55.
36. Lee J, Moran JP, Fenton BM, et al. Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer 2000;82:937-44.
37. Lee S, Zheng M, Deshpande S, et al. IL-12 suppresses the expression of ocular immunoinflammatory lesions by effects on angiogenesis. J Leukoc Biol 2002;71:469-76.
38. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827-35.
39. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-8.
40. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1993;85:499-500.
41. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
42. Lohr F, Herskind C, Lohr J, et al. Enhancement of the radiation response with interleukins/interferons. In: Milas L, Ang KK, Nieder C, eds. Biological modification of radiation response. Berlin-Heidelberg: Springer, 2003:205-26.
43. Lohr F, Hu K, Haroon Z, et al. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2000;2:195-203.
44. Maasilta P, Holsti LR, Halme M, et al. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;23:863-8.
45. Mahjoubi R, Bachouchi M, Munck JN, et al. Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head Neck 1993;15:115-8.
46. Malone C, Schiltz PM, Nayak SK, et al. Combination interferon-alpha2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro. Clin Cancer Res 1999;5:417-23.
47. McDonald S, Chang AY, Rubin P, et al. Combined Betaseron® (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:613-9.
48. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000;23:433-5.
49. Mertens R, Granzen B, Lassay L, et al. Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Gesellschaft für Pädiatrische Onkologie und Hämatologie. Cancer 1997;80:951-9.
50. Motzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001;21:257-63.
51. Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 2002;20:1429-30.
52. Nishisaka N, Maini A, Kinoshita Y, et al. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J Immunother 1999;22:308-14.
53. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000;179:367-71.
54. Packer RJ, Prados M, Phillips P, et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a Childrens Cancer Group phase I/II study. Cancer 1996;77:2150-6.
55. Park TK, Lee JP, Kim SN, et al. Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur J Gynaecol Oncol 1998;19:35-8.
56. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996;78:244-51.
57. Redman BG, Hillman GG, Flaherty L, et al. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. Clin Cancer Res 1998;4:283-6.
58. Robertson MJ, Cameron C, Atkins MB, et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999;5:9-16.
59. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75.
60. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
61. Ryu S, Kim OB, Kim SH, et al. In vitro radiosensitization of human cervical carcinoma cells by combined use of 13-cis-retinoic acid and interferon-alpha2a. Int J Radiat Oncol Biol Phys 1998;41:869-73.
62. Schafer U, Micke O, Muller SB, et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-34.
63. Schiller JH, Pugh M, Kirkwood JM, et al. Eastern Cooperative Group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 1996;2:29-36.
64. Schmidberger H, Rave-Frank M, Lehmann J, et al. The combined effect of interferon beta and radiation on five human tumor cell lines and embryonal lung fibroblasts. Int J Radiat Oncol Biol Phys 1999;43:405-12.
65. Schrijvers D, Johnson J, Jiminez U, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 1998;16:1054-9.
66. Seetharam S, Staba MJ, Schumm LP, et al. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol 1999;15:769-73.
67. Shaw EG, Deming RL, Creagan ET, et al. Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell Lung cancer. Int J Radiat Oncol Biol Phys 1995;31:827-31.
68. Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002;20:364-70.
69. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002;20:1361-7.
70. Strasly M, Cavallo F, Geuna M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001;166:3890-9.
71. Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 1998;5:481-90.
72. Teicher BA, Ara G, Buxton D, et al. Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig 1998;6:71-80.
73. Thomas R, Stea B. Radiation recall dermatitis from high-dose interferon alfa-2b. J Clin Oncol 2002;20:355-7.
74. Valavaara R, Kortekangas AE, Nordman E, et al. Interferon combined with irradiation in the treatment of operable head and neck carcinoma. A pilot study. Acta Oncol 1992;31:429-31.
75. Verastegui-Aviles E, Mohar A, Mota A, et al. Combination of radiation therapy and interferon alpha-2b in patients with advanced cervical carcinoma: a pilot study. Int J Gynecol Cancer 1999;9:401-5.
76. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
77. Younes E, Haas GP, Dezso B, et al. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol 1995;165:243-51.
78. Younes E, Haas GP, Dezso B, et al. Radiation-induced effects on murine kidney tumor cells: role in the interaction of local irradiation and immunotherapy. J Urol 1995;153:2029-33.